Revolutionary Finger-Prick Blood Test Offers Hope for Early Alzheimer’s Diagnosis
A groundbreaking international research project is underway to determine if a simple finger-prick blood test can accurately diagnose Alzheimer’s disease, potentially revolutionizing early detection and intervention for the devastating condition. The trial focuses on identifying key proteins in the blood associated with Alzheimer’s, offering a less invasive and more accessible alternative to current diagnostic methods like expensive brain scans and spinal taps.
Currently, diagnosing Alzheimer’s often requires costly and complex procedures that are not readily available to everyone. This new approach, utilizing a simple plasma separation card, aims to dramatically reduce both the cost and logistical hurdles associated with testing. The test doesn’t require refrigeration and can be shipped to laboratories at room temperature, making it ideal for wider implementation.
If successful, the test promises a scalable, accessible, and cost-effective screening method. Early diagnosis is critical, as it allows for earlier intervention and potentially delays the progression of Alzheimer’s or the onset of symptoms. “Over the last five years, there has been substantial progress in identifying blood-based biomarkers to identify people at high risk of developing Alzheimer’s disease before their symptoms present,” explained a senior official at LifeArc. “Developing cheaper, scalable and more accessible tests is vital in the battle against this devastating condition.”
The finger-prick test is a central component of the Global Alzheimer’s Platform Foundation® (GAP)’s Bio-Hermes-002 study, dedicated to advancing Alzheimer’s diagnosis through blood and digital biomarkers. GAP is collaborating with LifeArc, a non-profit medical research organization, and the UK Dementia Research Institute (UK DRI) with its Biomarker Factory.
As of January 19, 2026, the study has enrolled 883 of its 1000 target participants from 25 sites across the UK, USA, and Canada. The diverse participant pool includes individuals with no cognitive impairment, those with mild cognitive impairment, and some with mild to moderate Alzheimer’s disease. Over 360 participants have already completed the test.
Researchers are analyzing blood samples for three specific proteins – phosphorylated tau 217 (pTau217), Glial fibrillary acidic protein (GFAP), and Neurofilament light polypeptide (NfL) – considered blood-based biomarkers for the disease. These results will be compared with emerging blood-based and digital biomarker tests, such as speech analysis, retinal scans, and cognitive assessments, as well as the current gold standard of PET scans and MRI scans.
The current diagnostic process for Alzheimer’s is often invasive, expensive, and time-consuming, limiting access for individuals in areas with limited healthcare resources. This new blood test offers a potential solution to these challenges.
The potential impact extends beyond diagnosis. According to a statement from the President of GAP, “Using a simple blood test has the potential to revolutionize diagnosis by making a timely diagnosis accessible to more people, including those who have limited access to specialized healthcare.” This increased accessibility could allow more patients to participate in clinical trials for new drugs designed to slow disease progression in its early stages.
Professor Henrik Zetterberg, Lead of the Biomarker Factory at the UK Dementia Research Institute, emphasized the study’s scope and inclusivity. “This study is unique in its size and scope, with 30% of volunteers being recruited from under-represented groups,” he stated. “If successful, being able to diagnose Alzheimer’s with a minimally invasive, cost-effective method will revolutionise diagnostics in this area and pave the way for improved diagnosis of all neurodegenerative conditions.”
The urgency for improved diagnostics is underscored by personal stories like that of Dr. Michael Sandberg, a London GP. His mother, Aline, was diagnosed with Alzheimer’s, and he witnessed firsthand the devastating impact of the disease. He shared that his mother felt life wasn’t worth living if she could no longer enjoy activities she loved, like playing bridge and driving. Dr. Sandberg’s mother participated in a clinical trial that, he said, “gave her ‘more time as herself.’”
Dr. Emer MacSweeney, CEO and Medical Director of Re:Cognition Health, supports the BioHermes trial, stating that “Early, accurate biomarkers for Alzheimer’s disease are essential…As we approach a future in which Alzheimer’s moves into the preventative realm, this will be possible only with the availability of sensitive ubiquitous, inexpensive biomarkers.”
Dr. Sandberg himself expressed excitement about the Bio-Hermes-002 trial and relief at receiving a negative test result. “Being able to screen people to see if they are on the way to developing dementia without hugely expensive scans and lumbar punctures is going to be fundamental if we are to fulfil the potential of new treatments and develop simple and cost-effective tests.”
While further validation is needed before the test can be implemented within the National Health Service (NHS), the Bio-Hermes-002 study represents a significant step forward. The trial is expected to be completed in 2028.
A critical aspect of the study is its commitment to inclusivity. Researchers anticipate that at least 25% of volunteers will come from under-represented ethnic groups, addressing a significant health research gap. Black and Hispanic individuals are twice as likely to develop Alzheimer’s disease as white individuals, yet they are significantly underrepresented in clinical trials, with participation rates as low as 2% and rarely exceeding 20%. This disparity highlights the need for diverse data to ensure personalized medicine benefits all populations equally. .
The Bio-Hermes-002 project aims to gather data that will benefit all patients, regardless of ethnicity, paving the way for more equitable and effective Alzheimer’s care.
For further information or to arrange interviews, please contact Andrew Stewart, Director of Communications at LifeArc, at [email protected] or +447970293826.
SOURCE LifeArc
